Ellagic Acid Suppresses ApoB Secretion and Enhances ApoA-1 Secretion from Human Hepatoma Cells, HepG2.
HDL
HepG2
MTP
VLDL
apoA-1
apoB
ellagic acid
hepatoma
secretion
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
25 Jun 2021
25 Jun 2021
Historique:
received:
16
05
2021
revised:
15
06
2021
accepted:
21
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
15
7
2021
Statut:
epublish
Résumé
The effect of ellagic acid (EA), a naturally occurring polyphenolic compound, on the secretion of apolipoproteins from human hepatocytes, HepG2, was investigated. The levels of apoB and apoA-1 secreted in the cell culture medium were determined by sandwich ELISA. EA did not affect cell viability at the tested concentrations (up to 50 µM). EA suppressed the secretion of apoB and enhanced that of apoA-1 from HepG2 cells. However, cellular apoB levels were increased, suggesting that EA inhibited the trafficking of apoB during the process of secretion. In contrast, the increase in the cellular levels of apoA-1 was consistent with its secreted levels. These results indicate that EA inhibits the secretion of apoB from hepatocytes and increases the secretion of apoA-1. Both of these effects are beneficial for lipoprotein metabolism in the prevention of lifestyle-related diseases. The detailed mechanism underlying these effects of EA on lipoprotein metabolism should be elucidated in the future, but this naturally occurring polyphenolic compound might be antihyperlipidemic. Based on these results, EA is suggested as a candidate food-derived compound for the prevention of hyperlipidemia.
Identifiants
pubmed: 34202121
pii: molecules26133885
doi: 10.3390/molecules26133885
pmc: PMC8271888
pii:
doi:
Substances chimiques
APOA1 protein, human
0
APOB protein, human
0
Apolipoprotein A-I
0
Apolipoprotein B-100
0
Neoplasm Proteins
0
Ellagic Acid
19YRN3ZS9P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Strategic Project to Support the Formation of Research Bases at Private Universities," Matching Fund Subsidy from MEXT, 2011-2015
ID : S1101035
Références
Biosci Biotechnol Biochem. 2019 May;83(5):952-959
pubmed: 30741106
Atherosclerosis. 2006 Aug;187(2):363-71
pubmed: 16226266
Biochem Biophys Res Commun. 2012 Jan 13;417(2):880-5
pubmed: 22206671
Food Chem Toxicol. 2018 Apr;114:52-60
pubmed: 29438776
Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22145-50
pubmed: 21135223
Complement Ther Med. 2020 Jan;48:102236
pubmed: 31987256
Int J Vitam Nutr Res. 2006 May;76(3):147-51
pubmed: 17048194
Nutr Res. 2017 Oct;46:38-48
pubmed: 29173650
Nutr J. 2017 Oct 6;16(1):67
pubmed: 28985741
Biochemistry. 1985 Jul 30;24(16):4450-5
pubmed: 3931677
Curr Pharm Des. 2019;25(16):1817-1827
pubmed: 31298147
Circulation. 2013 Sep 10;128(11):1256-67
pubmed: 24019446
Circulation. 1999 Oct 26;100(17):1816-22
pubmed: 10534470
Molecules. 2017 Jan 24;22(1):
pubmed: 28125044
Diabetes. 2011 May;60(5):1446-57
pubmed: 21471511
Complement Ther Med. 2020 Mar;49:102358
pubmed: 32147056
Nature. 1970 Aug 15;227(5259):680-5
pubmed: 5432063
Biochemistry. 2003 Feb 11;42(5):1283-91
pubmed: 12564931
Pharmacol Res. 2017 Jan;115:149-161
pubmed: 27888156
Science. 1992 Nov 6;258(5084):999-1001
pubmed: 1439810
Cell Mol Life Sci. 2020 Jun;77(12):2367-2386
pubmed: 31471680
J Lipid Res. 2000 Sep;41(9):1481-94
pubmed: 10974056
Breast Cancer Res Treat. 2002 Feb;71(3):203-17
pubmed: 12002340
Circulation. 2012 Apr 17;125(15):1905-19
pubmed: 22508840
J Nutr. 2003 Mar;133(3):700-6
pubmed: 12612140
Diabetes. 2003 Oct;52(10):2554-61
pubmed: 14514640
J Agric Food Chem. 2000 Oct;48(10):4581-9
pubmed: 11052704
Am J Med. 1999 Aug 23;107(2A):16S-18S
pubmed: 10484232
J Lipid Res. 2002 Apr;43(4):557-64
pubmed: 11907138
Trends Cell Biol. 1995 Aug;5(8):317-21
pubmed: 14732096
J Hepatol. 2020 Jan;72(1):156-166
pubmed: 31568800
Biochem Biophys Res Commun. 2013 May 10;434(3):486-91
pubmed: 23583377
Phytother Res. 2015 Apr;29(4):501-8
pubmed: 25611333